Academia Sinica to work with GSK on genetic medicines

E020420X5 May. 2002（E33）

Source: Economic Daily News 04/20/2002

Translated by Jem Chung

 

    The Academia Sinica and the world's No. 1 pharmaceutical company, GSK, yesterday (Apr. 19) announced a strategic alliance on generic medicine research for the development of new drugs to treat five kinds of diseases which are related to diabetes, cardiovascular systems and asthma, and have higher morbidity rates in Asia than the rest of the world.  The research results will be shared by both parties.  This is the first genetic medicine research cooperation GSK has in Asia. 

GSK, the world's No. 1 pharmaceutical company, was given birth by the merger of two of the largest pharmaceutical plants worldwide, the English-based Glaxo Wellcome and the US-based SmithKline Beecham, in 2001.  Its annual revenue in 2001 is nearly US$30b with an operation scale equivalent to 10-time TSMC.  GSK has invested more than £2.4b (NT$120b) in R&D in year 2001 alone.  It currently has 24 research centers around the world and more than 15,000 researchers.

 

TIPLO ECARD Fireshot Video TIPLOBrochure_English TIPLO News Channel TIPLO TOUR 7th FIoor TIPLO TOUR 15th FIoor